915P Carboplatin in combination with three weekly paclitaxel as first line therapy in patients with recurrent/metastatic head and neck cancers: A regional cancer center experience

Abstract

HNC are the sixth most common malignancy diagnosed worldwide and is the most common cancer of males in India and treatment in recurrent/metastatic setting is challenging. For patients with R/M HNSSC, the EXTREME regimen has been established as standard of care in the first-line treatment for more than 10 years. However, many patients are not eligible for this regimen due to various reasons also including patients’ choice and logistics. This retrospective study aimed to evaluate the efficacy and tolerability of carboplatin and paclitaxel as first line treatment in patients with R/M HNC.